<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetol Metab Syndr</journal-id><journal-id journal-id-type="iso-abbrev">Diabetol Metab Syndr</journal-id><journal-title-group><journal-title>Diabetology &amp; Metabolic Syndrome</journal-title></journal-title-group><issn pub-type="epub">1758-5996</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28702091</article-id><article-id pub-id-type="pmc">5504981</article-id><article-id pub-id-type="publisher-id">252</article-id><article-id pub-id-type="doi">10.1186/s13098-017-0252-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Educ@dom: comparative study of the telemonitoring of patients with type 2 diabetes versus standard monitoring—study protocol for a randomized controlled study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2373-4889</contrib-id><name><surname>Turnin</surname><given-names>Marie-Christine</given-names></name><address><email>turnin.mc@chu-toulouse.fr</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Schirr-Bonnans</surname><given-names>Solène</given-names></name><address><email>solene.schirrbonnans@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Martini</surname><given-names>Jacques</given-names></name><address><email>martini.j@chu-toulouse.fr</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Buisson</surname><given-names>Jean-Christophe</given-names></name><address><email>buisson@enseeiht.fr</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Taoui</surname><given-names>Soumia</given-names></name><address><email>taoui.s@chu-toulouse.fr</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Chauchard</surname><given-names>Marie-Christine</given-names></name><address><email>chauchard.mc@chu-toulouse.fr</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Costa</surname><given-names>Nadège</given-names></name><address><email>costa.n@chu-toulouse.fr</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Lepage</surname><given-names>Benoît</given-names></name><address><email>lepage.b@chu-toulouse.fr</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Molinier</surname><given-names>Laurent</given-names></name><address><email>molinier.l@chu-toulouse.fr</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hanaire</surname><given-names>Hélène</given-names></name><address><email>hanaire.h@chu-toulouse.fr</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1457 2980</institution-id><institution-id institution-id-type="GRID">grid.411175.7</institution-id><institution>Department of Diabetology, Metabolic and Nutrition Diseases, </institution><institution>University Hospital of Toulouse, </institution></institution-wrap>1 Avenue Jean Poulhès, TSA 50032, 31059 Toulouse Cedex 9, France </aff><aff id="Aff2"><label>2</label>DIAMIP Network, Toulouse, France </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2176 6169</institution-id><institution-id institution-id-type="GRID">grid.15363.32</institution-id><institution></institution><institution>ENSEEIHT, </institution></institution-wrap>Toulouse, France </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1457 2980</institution-id><institution-id institution-id-type="GRID">grid.411175.7</institution-id><institution>Medical Information Department, </institution><institution>Toulouse University Hospital, </institution></institution-wrap>Toulouse, France </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1457 2980</institution-id><institution-id institution-id-type="GRID">grid.411175.7</institution-id><institution>Department of Epidemiology, </institution><institution>Toulouse University Hospital, </institution></institution-wrap>Toulouse, France </aff></contrib-group><pub-date pub-type="epub"><day>11</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>11</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>9</volume><elocation-id>52</elocation-id><history><date date-type="received"><day>7</day><month>2</month><year>2017</year></date><date date-type="accepted"><day>30</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>© The Author(s) 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title><offsets xml_i="6482" xml_f="6492" txt_i="11" txt_f="21">Background</offsets></title><p id="Par1"><offsets xml_i="6513" xml_f="7070" txt_i="22" txt_f="579">The global prevalence of type 2 diabetes is considerable. To avoid or delay its chronic complications, patients with type 2 diabetes should improve blood glucose management by adapting their life style. This involves changing the way in which diabetes is controlled. We believe that, thanks to technological innovations in connected health-monitoring devices, the telemonitoring of type 2 diabetes patients using therapeutic educational tools is likely to help them adapt their treatment and lifestyle habits, and therefore improve blood glucose management.</offsets></p></sec><sec><title><offsets xml_i="7092" xml_f="7099" txt_i="581" txt_f="588">Methods</offsets></title><p id="Par2"><offsets xml_i="7120" xml_f="7711" txt_i="589" txt_f="1180">This is a multicenter, randomized, controlled, prospective study. The primary objective is to compare the efficacy of telemonitoring to standard monitoring in terms of changes in glycated hemoglobin levels (HbA1c) after a 1 year follow-up period. The secondary objectives are clinical (changes in knowledge, physical activity, weight, etc.) and medical-economic. 282 patients are required (141 patients in each group) to satisfy the primary objective. For patients in the intervention group, the device will be given to them for 1 year and then withdrawn during the second year of follow-up.</offsets></p></sec><sec><title><offsets xml_i="7733" xml_f="7744" txt_i="1182" txt_f="1193">Conclusions</offsets></title><p id="Par3"><offsets xml_i="7765" xml_f="8245" txt_i="1194" txt_f="1674">The anticipated benefits of this research are an improvement in blood glucose management in patients with type 2 diabetes by improving their lifestyle whilst rationalizing recourse to consultations in order to reduce the incidence of complications and cost in the long term. If the results of this study show that management of type 2 diabetes by tele monitoring is clinically effective and economical, this device could then be made available to a larger diabetic patient cohort.</offsets></p></sec></abstract><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100006022</institution-id><institution>Ministère des Affaires Sociales, de la Santé et des Droits des Femmes</institution></institution-wrap></funding-source><award-id>PREPS 2012 No. 12-018-0078</award-id><principal-award-recipient><name><surname>Turnin</surname><given-names>Marie-Christine</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution>Conseil Régional Midi-Pyrénées</institution></funding-source><award-id>No. 11052617</award-id><award-id>No. 13050630</award-id><principal-award-recipient><name><surname>Turnin</surname><given-names>Marie-Christine</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title><offsets xml_i="9326" xml_f="9336" txt_i="1683" txt_f="1693">Background</offsets></title><p id="Par22"><offsets xml_i="9358" xml_f="9638" txt_i="1694" txt_f="1974">According to the World Health Organization (WHO), 422 million people suffer from diabetes world-wide. This qualifies as a genuine pandemic since progression is considerable. Thus the WHO is forecasting that 622 million people will be suffering from diabetes between now and 2040 [</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="9670" xml_f="9671" txt_i="1974" txt_f="1975">1</offsets></xref><offsets xml_i="9678" xml_f="10469" txt_i="1975" txt_f="2766">]. Over 90% of these people present type 2 diabetes. The severity of diabetes, from both a human and economic perspective, is the onset of chronic complications associated with the disease. To avoid or delay their onset as much as possible, patients with diabetes must improve the way in which they manage their blood glucose levels. Type 2 diabetes patients can be treated in different ways, depending on disease advance, ranging from a change in lifestyle alone, oral treatments or multiple insulin injections, or a combination of all options. The French Health Authorities (HAS) continue to advocate the following first-line therapy: a change in lifestyle with a change in diet and regular physical exercise for improved blood glucose management together with weight loss, if applicable [</offsets><xref ref-type="bibr" rid="CR2"><offsets xml_i="10501" xml_f="10502" txt_i="2766" txt_f="2767">2</offsets></xref><offsets xml_i="10509" xml_f="10511" txt_i="2767" txt_f="2769">, </offsets><xref ref-type="bibr" rid="CR3"><offsets xml_i="10543" xml_f="10544" txt_i="2769" txt_f="2770">3</offsets></xref><offsets xml_i="10551" xml_f="10781" txt_i="2770" txt_f="3000">]. These measures must be maintained long-term even when combined with medication. Numerous studies have shown that a change in lifestyle can improve patients’ blood glucose levels but long-term results are difficult to maintain [</offsets><xref ref-type="bibr" rid="CR4"><offsets xml_i="10813" xml_f="10814" txt_i="3000" txt_f="3001">4</offsets></xref><offsets xml_i="10821" xml_f="10822" txt_i="3001" txt_f="3002">–</offsets><xref ref-type="bibr" rid="CR6"><offsets xml_i="10854" xml_f="10855" txt_i="3002" txt_f="3003">6</offsets></xref><offsets xml_i="10862" xml_f="11105" txt_i="3003" txt_f="3246">]. Thanks to technological innovation, health-related devices can now be used to monitor patients remotely in their own homes and play a greater role in daily routines by helping patients to improve their lifestyle and adjust their treatment [</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="11137" xml_f="11138" txt_i="3246" txt_f="3247">7</offsets></xref><offsets xml_i="11145" xml_f="11146" txt_i="3247" txt_f="3248">–</offsets><xref ref-type="bibr" rid="CR12"><offsets xml_i="11179" xml_f="11181" txt_i="3248" txt_f="3250">12</offsets></xref><offsets xml_i="11188" xml_f="11190" txt_i="3250" txt_f="3252">].</offsets></p><p id="Par23"><offsets xml_i="11208" xml_f="11594" txt_i="3253" txt_f="3639">We want to compare telemonitoring management incorporating therapeutic education tools for type 2 diabetes with standard monitoring. We believe that this telemonitoring management approach will improve patients’ blood glucose levels, lifestyle and quality of life whilst rationalizing recourse to consultations, thus helping to reduce the incidence of complications and long-term costs.</offsets></p><sec id="Sec2"><title><offsets xml_i="11620" xml_f="11636" txt_i="3640" txt_f="3656">Study objectives</offsets></title><p id="Par24"><offsets xml_i="11658" xml_f="12604" txt_i="3657" txt_f="4603">The main objective is to compare the efficacy of telemonitoring versus standard monitoring in terms of changes in glycated hemoglobin (HbA1c) levels after a follow-up period of 1 year. Secondary objectives are changes in knowledge (evaluated using questionnaires focusing on dietetics and physical activity—GPAQ), hygiene and dietary approaches (3-day dietary questionnaires including 1 day at the weekend), quality of life (EQ 5D and DQOL questionnaires), clinical (weight, waist circumference) and laboratory parameters (lipid and mean glycemic fractions). These parameters are evaluated at baseline and after 1 year of follow-up. Patient and care satisfaction is also assessed after 1 year with continued efficacy (HbA1c) at 2 years. A medical-economic evaluation is also carried out and assessed after 1 and 2 years, respectively (cost-efficacy ratio, Markovian modelling for the longer term forecasting of medical and economic consequences).</offsets></p><p id="Par25"><offsets xml_i="12622" xml_f="12975" txt_i="4604" txt_f="4957">Secondary objectives, specifically for patients in the intervention group are combined with the use of connected devices. They are defined to describe changes; in diet, in nutritional knowledge, in the extent to which physical exercise is carried out, in weight and body composition, in mean blood glucose levels and patient acceptability of the device.</offsets></p></sec><sec id="Sec3"><title><offsets xml_i="13007" xml_f="13019" txt_i="4959" txt_f="4971">Study design</offsets></title><p id="Par26"><offsets xml_i="13041" xml_f="13287" txt_i="4972" txt_f="5218">A multicenter, open-label, randomized controlled trial in patients has been carried out with type 2 diabetes patients, comparing an intervention group with the telemonitoring device under study versus a control group based on standard monitoring.</offsets></p><p id="Par27"><offsets xml_i="13305" xml_f="13347" txt_i="5219" txt_f="5261">The study procedure is summarized in Fig. </offsets><xref rid="Fig1" ref-type="fig"><offsets xml_i="13379" xml_f="13380" txt_i="5261" txt_f="5262">1</offsets></xref><offsets xml_i="13387" xml_f="13388" txt_i="5262" txt_f="5263">.</offsets><fig id="Fig1"><label><offsets xml_i="13410" xml_f="13416" txt_i="5263" txt_f="5269">Fig. 1</offsets></label><caption><p><offsets xml_i="13436" xml_f="14379" txt_i="5269" txt_f="6212">Study design and schedule. Comparative, randomized, open, multicenter intervention trial with parallel-group evaluating a telemonitoring program for patients with type 2 diabetes, whose glycemic control can be improved, compared to a traditional optimized care. Patients are recruited during therapeutic educational sessions or appointments by general practitioners or diabetologists. If patients accept to participate to the study and sign up the protocol consent, they are randomized into two groups: one arm is trained to the telemonitoring device before receiving it at home, and the other arm keeps usual care. During 12 months, the intervention group uses the device, and health teams use the web platform to follow the measured parameters and to make appropriate decisions about health care of their patient. Biomedical and economic data are collected along the study to assess medical and cost impact of the device between the two arms</offsets></p></caption><graphic xlink:href="13098_2017_252_Fig1_HTML" id="MO1"></graphic></fig><offsets xml_i="14465" xml_f="14466" txt_i="6213" txt_f="6214">
</offsets></p></sec></sec><sec id="Sec4" sec-type="materials|methods"><title><offsets xml_i="14533" xml_f="14540" txt_i="6217" txt_f="6224">Methods</offsets></title><sec id="Sec5"><title><offsets xml_i="14570" xml_f="14618" txt_i="6225" txt_f="6273">Methods: participants, intervention and outcomes</offsets></title><sec id="Sec6"><title><offsets xml_i="14648" xml_f="14661" txt_i="6274" txt_f="6287">Study setting</offsets></title><p id="Par28"><offsets xml_i="14683" xml_f="14949" txt_i="6288" txt_f="6554">This study includes 16 patient recruitment investigating centers located throughout France: 5 university hospitals, one non-university medical center, a diabetology treatment network comprising 8 public and private health establishments and 2 independent physicians.</offsets></p></sec><sec id="Sec7"><title><offsets xml_i="14981" xml_f="15017" txt_i="6556" txt_f="6592">Inclusion and non-inclusion criteria</offsets></title><p id="Par29"><offsets xml_i="15039" xml_f="15111" txt_i="6593" txt_f="6665">The patient inclusion and non-inclusion criteria are presented in Table </offsets><xref rid="Tab1" ref-type="table"><offsets xml_i="15145" xml_f="15146" txt_i="6665" txt_f="6666">1</offsets></xref><offsets xml_i="15153" xml_f="15154" txt_i="6666" txt_f="6667">.</offsets><table-wrap id="Tab1"><label><offsets xml_i="15183" xml_f="15190" txt_i="6667" txt_f="6674">Table 1</offsets></label><caption><p><offsets xml_i="15210" xml_f="15256" txt_i="6674" txt_f="6720">Patient’s inclusion and non-inclusion criteria</offsets></p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left"><offsets xml_i="15335" xml_f="15353" txt_i="6721" txt_f="6739">Inclusion criteria</offsets></td></tr><tr><td align="left"><offsets xml_i="15384" xml_f="15413" txt_i="6740" txt_f="6769"> Patient with type 2 diabetes</offsets></td></tr><tr><td align="left"><offsets xml_i="15444" xml_f="15473" txt_i="6770" txt_f="6799"> Patient over 18 years of age</offsets></td></tr><tr><td align="left"><offsets xml_i="15504" xml_f="15595" txt_i="6800" txt_f="6888"> Presenting blood glucose profile characterised by HbA1c levels ranging from &gt;6.5 to 10%</offsets></td></tr><tr><td align="left"><offsets xml_i="15626" xml_f="15651" txt_i="6889" txt_f="6914"> With and without insulin</offsets></td></tr><tr><td align="left"><offsets xml_i="15682" xml_f="15720" txt_i="6915" txt_f="6953"> Having an internet connection at home</offsets></td></tr><tr><td align="left"><offsets xml_i="15751" xml_f="15815" txt_i="6954" txt_f="7018"> Agreeing to the training methods and to hire and use the device</offsets></td></tr><tr><td align="left"><offsets xml_i="15846" xml_f="15884" txt_i="7019" txt_f="7057"> Belonging to a social security system</offsets></td></tr><tr><td align="left"><offsets xml_i="15915" xml_f="15988" txt_i="7058" txt_f="7131"> Having given his/her informed consent and having signed the consent form</offsets></td></tr><tr><td align="left"><offsets xml_i="16019" xml_f="16041" txt_i="7132" txt_f="7154">Non-inclusion criteria</offsets></td></tr><tr><td align="left"><offsets xml_i="16072" xml_f="16102" txt_i="7155" txt_f="7185"> Subject with reduced mobility</offsets></td></tr><tr><td align="left"><offsets xml_i="16133" xml_f="16166" txt_i="7186" txt_f="7219"> Subject living in an institution</offsets></td></tr><tr><td align="left"><offsets xml_i="16197" xml_f="16253" txt_i="7220" txt_f="7276"> Women wishing to have a baby, pregnancy, breast-feeding</offsets></td></tr><tr><td align="left"><offsets xml_i="16284" xml_f="16331" txt_i="7277" txt_f="7324"> Person participating in another clinical trial</offsets></td></tr><tr><td align="left"><offsets xml_i="16362" xml_f="16408" txt_i="7325" txt_f="7371"> Person placed under a legal protection system</offsets></td></tr><tr><td align="left"><offsets xml_i="16439" xml_f="16585" txt_i="7372" txt_f="7515"> Serious disease of recent onset (&lt;3 months) or decompensated disorder likely to affect the patient’s blood glucose management in the long term</offsets></td></tr><tr><td align="left"><offsets xml_i="16616" xml_f="16644" txt_i="7516" txt_f="7544"> Confirmed haemoglobinopathy</offsets></td></tr><tr><td align="left"><offsets xml_i="16675" xml_f="16719" txt_i="7545" txt_f="7589"> Visual, intellectual or physical impairment</offsets></td></tr><tr><td align="left"><offsets xml_i="16750" xml_f="16814" txt_i="7590" txt_f="7654"> Inability to understand all or some of the software information</offsets></td></tr><tr><td align="left"><offsets xml_i="16845" xml_f="16916" txt_i="7655" txt_f="7726"> Retinal status not permitting optimisation of blood glucose management</offsets></td></tr><tr><td align="left"><offsets xml_i="16947" xml_f="17018" txt_i="7727" txt_f="7795"> Confirmed severe renal impairment (creatinine clearance &lt;30 ml/min)</offsets></td></tr><tr><td align="left"><offsets xml_i="17049" xml_f="17086" txt_i="7796" txt_f="7833"> Person with severe dietary disorders</offsets></td></tr><tr><td align="left"><offsets xml_i="17117" xml_f="17179" txt_i="7834" txt_f="7896"> Person having undergone or about to undergo bariatric surgery</offsets></td></tr><tr><td align="left"><offsets xml_i="17210" xml_f="17261" txt_i="7897" txt_f="7948"> Person with an implanted electronic medical device</offsets></td></tr></tbody></table></table-wrap><offsets xml_i="17300" xml_f="17301" txt_i="7949" txt_f="7950">
</offsets></p></sec><sec id="Sec8"><title><offsets xml_i="17333" xml_f="17345" txt_i="7952" txt_f="7964">Intervention</offsets></title><p id="Par30"><offsets xml_i="17367" xml_f="18009" txt_i="7965" txt_f="8607">Subjects are recruited from several investigating centers. After obtaining an informed consent, clinical examination is performed by the physician and questionnaires are collected. Patients are randomized into two groups: one arm is trained by the research staff on the telemonitoring device before receiving it at home through a demonstration device to familiarize with the connected objects. Instructions for use and the phone number of the project team are given to patients. Within 15 days a specialist in Health equipment, previously formed, comes in the patient home to install the device and explain to them the operation if necessary.</offsets></p><p id="Par31"><offsets xml_i="18027" xml_f="18165" txt_i="8608" txt_f="8746">A hotline managed by our service provider is also available to patients to prevent them from experiencing technical or operational issues.</offsets></p><p id="Par32"><offsets xml_i="18183" xml_f="18511" txt_i="8747" txt_f="9075">During 12 months, the intervention group uses the device, and health teams use the web service to follow the measured parameters and to make appropriate decisions about health care of their patients. Biomedical and economic data are collected along the study to assess medical and cost impact of the device between the two arms.</offsets></p><p id="Par33"><offsets xml_i="18529" xml_f="18566" txt_i="9076" txt_f="9113">The other arm keeps usual care (Fig. </offsets><xref rid="Fig1" ref-type="fig"><offsets xml_i="18598" xml_f="18599" txt_i="9113" txt_f="9114">1</offsets></xref><offsets xml_i="18606" xml_f="18608" txt_i="9114" txt_f="9116">).</offsets></p></sec><sec id="Sec9"><title><offsets xml_i="18640" xml_f="18668" txt_i="9118" txt_f="9146">Telemonitoring device (Fig. </offsets><xref rid="Fig2" ref-type="fig"><offsets xml_i="18700" xml_f="18701" txt_i="9146" txt_f="9147">2</offsets></xref><offsets xml_i="18708" xml_f="18709" txt_i="9147" txt_f="9148">)</offsets></title><p id="Par34"><offsets xml_i="18731" xml_f="18869" txt_i="9149" txt_f="9287">Tele-monitoring device available for use by type 2 diabetes patients in their own homes includes three educational software applications [</offsets><xref ref-type="bibr" rid="CR13"><offsets xml_i="18902" xml_f="18904" txt_i="9287" txt_f="9289">13</offsets></xref><offsets xml_i="18911" xml_f="18912" txt_i="9289" txt_f="9290">–</offsets><xref ref-type="bibr" rid="CR15"><offsets xml_i="18945" xml_f="18947" txt_i="9290" txt_f="9292">15</offsets></xref><offsets xml_i="18954" xml_f="19120" txt_i="9292" txt_f="9458">] focusing on a balanced diet and physical activity, available on tablets, and biomedical data sensors (scales with impedancemetry, actimeter, blood glucose monitor).</offsets><fig id="Fig2"><label><offsets xml_i="19142" xml_f="19148" txt_i="9458" txt_f="9464">Fig. 2</offsets></label><caption><p><offsets xml_i="19168" xml_f="19675" txt_i="9464" txt_f="9971">Telemonitoring devices available for the patient at home. A telemonitoring device with educational tools is given to people with type 2 diabetes at their home. It is composed of three software applications available on a tablet to improve eating habits, a self-monitoring blood glucose device, a connected scale to measure weight and fat mass, and a pedometer to evaluate physical activity. Secured web services are used to send and store data and to deliver a synthesis to patients and health professionals</offsets></p></caption><graphic xlink:href="13098_2017_252_Fig2_HTML" id="MO2"></graphic></fig><offsets xml_i="19761" xml_f="19762" txt_i="9972" txt_f="9973">
</offsets></p><sec id="Sec10"><title><offsets xml_i="19789" xml_f="19809" txt_i="9974" txt_f="9994">Educational software</offsets></title><p id="Par35"><offsets xml_i="19831" xml_f="20010" txt_i="9995" txt_f="10174">Patients in the telemonitoring arm will have a tablet at home which they can use to access 3 interactive educational software applications: Nutri-Educ, Nutri-Kiosk and Acti-Kiosk.</offsets></p><p id="Par36"><offsets xml_i="20028" xml_f="20159" txt_i="10175" txt_f="10306">Nutri-Educ is a personalized nutritional educational software application that meets international clinical trial recommendations [</offsets><xref ref-type="bibr" rid="CR16"><offsets xml_i="20192" xml_f="20194" txt_i="10306" txt_f="10308">16</offsets></xref><offsets xml_i="20201" xml_f="20505" txt_i="10308" txt_f="10612">]. It allows patients for whom a profile and nutritional requirement record has been created to enter their meals (in the form of photos with various portions of food), to establish whether or not their meals are balanced and to obtain one or more suggestions for improving the nutritional balance (Fig. </offsets><xref rid="Fig3" ref-type="fig"><offsets xml_i="20537" xml_f="20538" txt_i="10612" txt_f="10613">3</offsets></xref><offsets xml_i="20545" xml_f="20788" txt_i="10613" txt_f="10856">). These meals can be recorded and used in the patient telemonitoring process. Based on feedback from the teaching units in our department of Diabetology, we assessed that asking for the description of six meals per month is the most feasible.</offsets><fig id="Fig3"><label><offsets xml_i="20810" xml_f="20816" txt_i="10856" txt_f="10862">Fig. 3</offsets></label><caption><p><offsets xml_i="20836" xml_f="22168" txt_i="10862" txt_f="12194">An example of meal with a proposition of correction to improve the nutritional balance. Nutri-Educ is an interactive, educational, nutrition software application that provides personalized help in the composition of meals. Each user has a personalized folder that contains some of its physiopathological characteristics. It was developed by the department of Diabetology of the University Hospital of Toulouse in collaboration with a computer engineer. It has several features: the system evaluates the energy needs of the subjects by a set of rules, taking into account age, sex, size, physical activity. The caloric goal is then adapted according to the BMI of the subject. It helps the user to balance his meals with personalized advice. It takes into account the daily fractionation of the feed. The user enters the foods that make up his/her meal with photos to choose the type of food and its portion. Nutri-Educ makes a diagnosis of the meal calorically and on the carbohydrate-lipid-protein distribution according to the international recommendations. It mentions the lack of fiber, calcium… and then indicates several food combinations involved in the imbalance of the meal. It is able to offer balanced meal solutions from the foods seized by the user while trying to respect the choices of the subject as well as possible</offsets></p></caption><graphic xlink:href="13098_2017_252_Fig3_HTML" id="MO3"></graphic></fig><offsets xml_i="22254" xml_f="22255" txt_i="12195" txt_f="12196">
</offsets></p><p id="Par37"><offsets xml_i="22273" xml_f="22516" txt_i="12197" txt_f="12440">Patients are asked to enter 2 breakfasts, 2 lunches and 2 dinners per month as a minimum requirement. Nutri-Kiosk is a series of quizzes which test patients’ nutritional knowledge. EDUC@DOM patients are advised to use it at least once a month.</offsets></p><p id="Par38"><offsets xml_i="22534" xml_f="22788" txt_i="12441" txt_f="12695">Acti-Kiosk is a software application that allows patients to assess their physical activity/sedentary behavior. It gives tips on how to start up a physical exercise program (warm-ups, stretching, adjusting the bicycle saddle, etc.) in the form of videos.</offsets></p></sec><sec id="Sec11"><title><offsets xml_i="22821" xml_f="22845" txt_i="12697" txt_f="12721">Connected health devices</offsets></title><p id="Par39"><offsets xml_i="22867" xml_f="23593" txt_i="12722" txt_f="13448">In addition to these education software applications, connected health devices form part of the telemonitoring system: connected blood glucose monitor to record blood glucose readings taken by patients, a connected scale with impedancemetry to monitor weight (with fat mass and lean mass) and an actimeter to monitor physical activity (number of steps taken, climbing stairs or hills, intensity of the activity). Some of the connected devices such as the scales do not require any intervention on the part of the patient to send the data, whilst others require data to be downloaded (blood glucose monitor) or the device has to be positioned next to the tablet (actimeter). Patients are asked to submit their data once a week.</offsets></p></sec><sec id="Sec12"><title><offsets xml_i="23626" xml_f="23657" txt_i="13450" txt_f="13481">The web telemonitoring platform</offsets></title><p id="Par40"><offsets xml_i="23679" xml_f="23932" txt_i="13482" txt_f="13735">All of these data are sent to a secure web platform. A software application translates these data in the form of graphs and charts to produce a summary that can be accessed by the doctor and by the patient via the tablet, on request. This summary (Fig. </offsets><xref rid="Fig4" ref-type="fig"><offsets xml_i="23964" xml_f="23965" txt_i="13735" txt_f="13736">4</offsets></xref><offsets xml_i="23972" xml_f="24295" txt_i="13736" txt_f="14059">) includes an initial display of data over the last 30 days (weight, number of steps taken, intensity of the physical activity, targets in the form of benchmarks for meals, blood glucose diary) with a month-by-month average of the various follow-up parameters. All of the meals entered by the patients can also be accessed.</offsets><fig id="Fig4"><label><offsets xml_i="24317" xml_f="24323" txt_i="14059" txt_f="14065">Fig. 4</offsets></label><caption><p><offsets xml_i="24343" xml_f="25311" txt_i="14065" txt_f="15033">Remote monitoring report summarizes the important parameters of diabetes. A module on the tablet will synthesize all of this information and provide an assessment to the patient at the time of his choice in the form of tables and graphs: weight curve, evolution of pre- and postprandial glycemic averages, Physical activity (number of steps recorded by the actimeter, number of stages assembled, time of physical inactivity), evolution of dietary behavior (evolution of caloric intake and quality of nutrients (calories, carbohydrates, lipids, proteins…). This module will send technical alerts to the project team if the tools are not used. A module available on a secure server will store and synthesize this data and make it available to caregivers (general practitioners, diabetologists, and dieticians) in monthly synthesis form. They will be able to see this synthesis which will enable them to refocus their objectives relative to patients in a personalized way</offsets></p></caption><graphic xlink:href="13098_2017_252_Fig4_HTML" id="MO4"></graphic></fig><offsets xml_i="25397" xml_f="25398" txt_i="15034" txt_f="15035">
</offsets></p><p id="Par41"><offsets xml_i="25416" xml_f="25725" txt_i="15036" txt_f="15345">Using this platform, the investigators can also access the patient record and can amend the targets initially predicted at the inclusion visit that patients have to reach over time: number of steps, blood glucose targets or weight. These objectives are also viewable by the patient in the summary at any time.</offsets></p><p id="Par42"><offsets xml_i="25743" xml_f="26482" txt_i="15346" txt_f="16085">In the intervention group, patients are remotely monitored for the first year and are then followed up according to standard procedure in the second year. No consultation is scheduled in advance during the telemonitoring year. Consultations can take place at the request of doctors or patients, if required. An e-mail is sent to investigators once a month to remind them to remotely monitor their patients. Medical alerts are programmed and can be adapted for individual patients and e-mailed to investigating physicians with a link to connect to the monitoring platform. These alerts highlight hypoglycemia with cases of hyperglycemia accounting for over 30% of the blood glucose levels recorded, and excessive weight loss or weight gain.</offsets></p><p id="Par43"><offsets xml_i="26500" xml_f="26839" txt_i="16086" txt_f="16425">In this study a hypoglycemia alert is triggered when the patient’s blood glucose level is under 3.3 mmol/l (59.45 mg/dl) and a hyperglycemia alert is triggered when the patient’s blood glucose level is over 8.8 mmol/l (160 mg/dl). However, these thresholds are modular and can be adjusted by the physician according to the patient profile.</offsets></p><p id="Par44"><offsets xml_i="26857" xml_f="27078" txt_i="16426" txt_f="16647">These alerts should not be viewed as emergency cases but provide investigators with information on events over the last 15–30 days. There is no procedure to follow the physician judge the therapeutic action to be brought.</offsets></p><p id="Par45"><offsets xml_i="27096" xml_f="27424" txt_i="16648" txt_f="16976">The project team receives technical alerts by e-mail. These technical alerts inform the project team if patients have not connected to the system for more than 15 days. In response, they contact the patients via the platform e-mailing system or by telephone to resolve any technical problems provide advice or motivate patients.</offsets></p></sec><sec id="Sec13"><title><offsets xml_i="27457" xml_f="27484" txt_i="16978" txt_f="17005">The secure messaging system</offsets></title><p id="Par46"><offsets xml_i="27506" xml_f="27573" txt_i="17006" txt_f="17073">A secure messaging system facilitates patient contact and coaching.</offsets></p><p id="Par47"><offsets xml_i="27591" xml_f="27677" txt_i="17074" txt_f="17160">The physician according to the telemonitoring sends messages to patients for coaching.</offsets></p><p id="Par48"><offsets xml_i="27695" xml_f="27805" txt_i="17161" txt_f="17271">Patients can choose the receiver of the message depending on the nature of the request (medical or technical).</offsets></p></sec><sec id="Sec14"><title><offsets xml_i="27838" xml_f="27863" txt_i="17273" txt_f="17298">The telemonitoring report</offsets></title><p id="Par49"><offsets xml_i="27885" xml_f="28133" txt_i="17299" txt_f="17547">Investigators are asked to provide a telemonitoring report in the form of a pop-up menu. They are required to sign the telemonitoring document and provide an estimate of the amount of time spent on telemonitoring from a medical-economic standpoint.</offsets></p></sec></sec><sec id="Sec15"><title><offsets xml_i="28172" xml_f="28180" txt_i="17550" txt_f="17558">Outcomes</offsets></title><p id="Par50"><offsets xml_i="28202" xml_f="28455" txt_i="17559" txt_f="17812">The primary endpoint is the difference between HbA1c level after 1 year of follow-up and the targeted HbA1c level defined at baseline by the physician in charge of the patient (based on the recommended strategy for glycemic control in type 2 diabetes) [</offsets><xref ref-type="bibr" rid="CR17"><offsets xml_i="28488" xml_f="28490" txt_i="17812" txt_f="17814">17</offsets></xref><offsets xml_i="28497" xml_f="28499" txt_i="17814" txt_f="17816">, </offsets><xref ref-type="bibr" rid="CR18"><offsets xml_i="28532" xml_f="28534" txt_i="17816" txt_f="17818">18</offsets></xref><offsets xml_i="28541" xml_f="28706" txt_i="17818" txt_f="17983">]. HbA1c levels are measured by high-performance liquid chromatographic (HPLC) methods HbA1c levels will be measured at baseline, 3, 6, 9 and 12 months of follow-up.</offsets></p><p id="Par51"><offsets xml_i="28724" xml_f="28751" txt_i="17984" txt_f="18011">The secondary outcomes are:</offsets></p><p id="Par52"><offsets xml_i="28769" xml_f="28861" txt_i="18012" txt_f="18104">Comparison between the two arms for assessment at baseline and after 1 year of follow-up of:</offsets><list list-type="bullet"><list-item><p id="Par53"><offsets xml_i="28911" xml_f="28990" txt_i="18104" txt_f="18183">Improvement of nutritional knowledge, questionnaires will be given to patients.</offsets></p></list-item><list-item><p id="Par54"><offsets xml_i="29031" xml_f="29109" txt_i="18184" txt_f="18262">Dietary intake measured by a validated food survey based on 3-day food record.</offsets></p></list-item><list-item><p id="Par55"><offsets xml_i="29150" xml_f="29240" txt_i="18263" txt_f="18353">Physical activity practice, measured by the general physical activity questionnaire (GPAQ.</offsets></p></list-item><list-item><p id="Par56"><offsets xml_i="29281" xml_f="29359" txt_i="18354" txt_f="18432">Body composition, BMI (body mass index), waist circumference will be measured.</offsets></p></list-item><list-item><p id="Par57"><offsets xml_i="29400" xml_f="29476" txt_i="18433" txt_f="18509">Mean of blood glycaemia, self-monitoring blood glucose books will be copied.</offsets></p></list-item><list-item><p id="Par58"><offsets xml_i="29517" xml_f="29644" txt_i="18510" txt_f="18637">Total cholesterol, triglycerides and high density lipoprotein (HDL) cholesterol blood levels, a blood sample will be collected.</offsets></p></list-item><list-item><p id="Par59"><offsets xml_i="29685" xml_f="29805" txt_i="18638" txt_f="18758">Quality of life of patients, measured by the diabetes quality of life questionnaire (DQOL) and the EQ-5D questionnaires.</offsets></p></list-item></list><offsets xml_i="29828" xml_f="29829" txt_i="18759" txt_f="18760">
</offsets></p><p id="Par60"><offsets xml_i="29847" xml_f="30386" txt_i="18761" txt_f="19300">Direct and indirect costs will be recorded at baseline, throughout the study and at the closure visit. The economic analysis will be carried out from the cost payer’s point of view, Assurance Maladie (Health Insurance). Direct medical costs (directly attributable to patient treatment), direct costs of a non-medical nature (travelling expenses and the costs incurred through implementing the telemonitoring programme) and indirect costs (production losses) to be paid by health insurance, mutual insurance and patients will be calculated.</offsets></p><p id="Par61"><offsets xml_i="30404" xml_f="30528" txt_i="19301" txt_f="19425">Specifically for the intervention group, assessment of the evolution of parameters collected with the telemonitoring device.</offsets><list list-type="bullet"><list-item><p id="Par62"><offsets xml_i="30578" xml_f="30646" txt_i="19425" txt_f="19493">Food behavior through meals registered with the Nutri-Educ software.</offsets></p></list-item><list-item><p id="Par63"><offsets xml_i="30687" xml_f="30776" txt_i="19494" txt_f="19583">Nutritional knowledge through rate of good choices playing games of Nutri-Kiosk software.</offsets></p></list-item><list-item><p id="Par64"><offsets xml_i="30817" xml_f="30934" txt_i="19584" txt_f="19701">Physical activity measures collected with the podometer (number of steps, number of stairs climbed up and intensity).</offsets></p></list-item><list-item><p id="Par65"><offsets xml_i="30975" xml_f="31033" txt_i="19702" txt_f="19760">Weight, fat rate and lean rate collected with the balance.</offsets></p></list-item><list-item><p id="Par66"><offsets xml_i="31074" xml_f="31149" txt_i="19761" txt_f="19836">Means of glycaemia collected with the self-monitoring blood glucose device.</offsets></p></list-item><list-item><p id="Par67"><offsets xml_i="31190" xml_f="31369" txt_i="19837" txt_f="20016">Acceptability and satisfaction of the telemonitoring system by the patients with the number and time of connections during the 1st year of follow-up and a questionnaire at 1 year.</offsets></p></list-item><list-item><p id="Par68"><offsets xml_i="31410" xml_f="31667" txt_i="20017" txt_f="20274">Acceptability and satisfaction of the telemonitoring system by the health professionals with the number and time of connections leading to a medical decision (phone call or medical appointment) during the 1st year of follow-up and a questionnaire at 1 year.</offsets></p></list-item></list><offsets xml_i="31690" xml_f="31691" txt_i="20275" txt_f="20276">
</offsets></p></sec><sec id="Sec16"><title><offsets xml_i="31724" xml_f="31751" txt_i="20278" txt_f="20305">Study duration and schedule</offsets></title><p id="Par69"></p></sec><sec id="Sec17"><title><offsets xml_i="31806" xml_f="31817" txt_i="20308" txt_f="20319">Sample size</offsets></title><p id="Par70"><offsets xml_i="31839" xml_f="31920" txt_i="20320" txt_f="20401">The sample size was calculated using the approach proposed by Frison and Pocock [</offsets><xref ref-type="bibr" rid="CR19"><offsets xml_i="31953" xml_f="31955" txt_i="20401" txt_f="20403">19</offsets></xref><offsets xml_i="31962" xml_f="32716" txt_i="20403" txt_f="21157">]. The calculation is based on the comparison between the two study arms of the mean of 4 post-treatment measurements during the 1st year of follow-up (at 3, 6, 9 and 12 months). Assuming a standard deviation of 2 points of HbA1c, a correlation of 0.4 between the pre- and post-randomization measurements, and a correlation of 0.5 between the post-randomization measurements, 117 patients are required per arm (234 patients in all) to detect a difference of 0.5 points of HbA1c with a power of 80%, a two-sided type I error of 5%. This calculation was computed using Stata SE 11.2 software. To avoid any loss of power due to patients lost to follow-up, the cohort obtained is increased by 20% to give a total of 282 patients to be enrolled (141 per arm).</offsets></p></sec><sec id="Sec18"><title><offsets xml_i="32749" xml_f="32759" txt_i="21159" txt_f="21169">Allocation</offsets></title><p id="Par71"><offsets xml_i="32781" xml_f="33343" txt_i="21170" txt_f="21729">Randomization was based on a 1:1 ratio and stratified on the baseline HbA1c level (&lt;7.5% vs ≥7.5%). The allocation sequence was randomly permuted in blocks of varying size (2, 4 or 6), generated by computer (Stata SE 11.2, ralloc procedure) by the methodologist. There was no blinding procedure in this open-label trial, however randomization was centralized at the Toulouse University Hospital and managed by the project manager and the two clinical research associates, and the allocation sequence was unknown to the investigators who enrolled participants.</offsets></p></sec><sec id="Sec19"><title><offsets xml_i="33376" xml_f="33398" txt_i="21731" txt_f="21753">Data collection method</offsets></title><p id="Par72"><offsets xml_i="33420" xml_f="33673" txt_i="21754" txt_f="22007">Data are collected by the investigators, study staff and by patients called PROs (patient report outcomes) PROs. Hba1c levels, serum lipid profile, clinical exam and questionnaires were recorded on an e-crf (e-clinical report form) by single data entry.</offsets></p><p id="Par73"><offsets xml_i="33691" xml_f="33889" txt_i="22008" txt_f="22206">Quarterly, the CRAs (clinical research associate) call the patients, over the 2-year period, to obtain protocol-related information: result of the HbA1c assay, medical treatments and adverse events.</offsets></p><p id="Par74"><offsets xml_i="33907" xml_f="34487" txt_i="22207" txt_f="22787">Data obtained using biomedical sensors will be retained. Range checks were implemented to limit data entry mistakes on the e-crf. All the data obtained from the various sources (biomedical sensors, tablet, data entered by the clinicians, data entered by the CRA) will be merged into a single complete database. A simple input will be made on an input mask with logical controls for the clinical data. The data will be validated according to the data management plan defined jointly by the coordinating investigator and the epidemiology department (methodologist and statistician).</offsets></p><p id="Par75"><offsets xml_i="34505" xml_f="34852" txt_i="22788" txt_f="23135">The data will be frozen after the last logical and coherence checks carried out at the beginning of the statistical analysis. Once all the CRFs have been entered and validated, and all the steps of the Data Management have been locked, the Data Manager can proceed to freeze the database, a certificate of which will be issued to the Project team.</offsets></p><p id="Par76"><offsets xml_i="34870" xml_f="34987" txt_i="23136" txt_f="23253">The database will then be provided to the Statistician for analysis in accordance with the statistical analysis plan.</offsets></p></sec><sec id="Sec20"><title><offsets xml_i="35020" xml_f="35039" txt_i="23255" txt_f="23274">Statistical methods</offsets></title><sec id="Sec21"><title><offsets xml_i="35070" xml_f="35089" txt_i="23275" txt_f="23294">Analysis population</offsets></title><p id="Par77"><offsets xml_i="35111" xml_f="35578" txt_i="23295" txt_f="23762">Efficacy will be analyzed on an intent-to-treat (ITT) basis followed by a per protocol (PP) analysis, if required. The PP analysis will only be carried out if the ITT population differs from the PP population by more than 10%. A flow chart will be described and a detailed descriptive analysis of the distribution of baseline variables in the study population will be carried out per arm in order to check the randomization result (intervention/control) and globally.</offsets></p></sec><sec id="Sec22"><title><offsets xml_i="35611" xml_f="35635" txt_i="23764" txt_f="23788">Primary outcome analysis</offsets></title><p id="Par78"><offsets xml_i="35657" xml_f="36705" txt_i="23789" txt_f="24837">The primary outcome (difference between HbA1c level after 1 year of follow-up and baseline targeted HbA1c level) will be compared between the two groups. The difference between the the intervention and control groups will be assessed firstly using bivariate analysis (Student’s T test), and secondly using mixed model analysis for repeated measures. The mixed model will be adjusted for the baseline value of HbA1c, as well as additional baseline variables that might be potential confounders: center, age, gender, treatment by insulin, duration of diabetes and history of diabetes complications. To manage missing data, a sensitivity analysis using the last observation carried forward (LOCF) technique will be applied. Secondary outcomes will be analyzed according to the same principles. A bivariate analysis will be computed, followed by a multivariate analysis of covariance (ANCOVA) adjusted for the baseline value of the corresponding secondary outcome and the same set of potential baseline confounders than in the primary outcome analysis.</offsets></p></sec><sec id="Sec23"><title><offsets xml_i="36738" xml_f="36775" txt_i="24839" txt_f="24876">Methods for medical-economic analysis</offsets></title><p id="Par79"><offsets xml_i="36797" xml_f="36839" txt_i="24877" txt_f="24919">A cost/efficacy ratio will be established:</offsets></p><p id="Par80"><offsets xml_i="36857" xml_f="36932" txt_i="24920" txt_f="24995">Differential RCE = Δ Cost between strategies/Δ Efficacy between strategies.</offsets></p><p id="Par81"><offsets xml_i="36950" xml_f="37155" txt_i="24996" txt_f="25201">Markovian modelling can be used for the precise estimation of the various costs incurred by the diabetes treatment strategies and the medical repercussions over the 2-year period including published data [</offsets><xref ref-type="bibr" rid="CR20"><offsets xml_i="37188" xml_f="37190" txt_i="25201" txt_f="25203">20</offsets></xref><offsets xml_i="37197" xml_f="37199" txt_i="25203" txt_f="25205">, </offsets><xref ref-type="bibr" rid="CR21"><offsets xml_i="37232" xml_f="37234" txt_i="25205" txt_f="25207">21</offsets></xref><offsets xml_i="37241" xml_f="37305" txt_i="25207" txt_f="25271">] and expert advice. A sensitivity analysis will be carried out.</offsets></p></sec></sec><sec id="Sec24"><title><offsets xml_i="37344" xml_f="37359" txt_i="25274" txt_f="25289">Data monitoring</offsets></title><p id="Par82"><offsets xml_i="37381" xml_f="37620" txt_i="25290" txt_f="25529">A clinical Research associate mandated by the promotor visits regularly each study site and performs all types of site visits including, but not limited to, qualification visits, initiation visits, monitoring visits and termination visits.</offsets></p><p id="Par83"><offsets xml_i="37638" xml_f="38005" txt_i="25530" txt_f="25897">During the site visits the CRA will monitor the informed consent, ensure the trial is conducted in compliance with the protocol, ICH/GCP, applicable regulatory requirements and applicable SOPs/work instructions. The CRA will be responsible with trial monitoring on-site of clinical data for accuracy and completeness, and clinical report preparation and presentation.</offsets></p></sec><sec id="Sec25"><title><offsets xml_i="38038" xml_f="38074" txt_i="25899" txt_f="25935">Declaration of serious adverse event</offsets></title><p id="Par84"><offsets xml_i="38096" xml_f="38167" txt_i="25936" txt_f="26007">The investigator evaluates each adverse event in terms of its severity.</offsets></p><p id="Par85"><offsets xml_i="38185" xml_f="38379" txt_i="26008" txt_f="26202">The pharmacovigilance unit of the Toulouse University Hospital has established a specific form to be completed by the investigator who declares the SAE (serious adverse event) and sends it back.</offsets></p><p id="Par86"><offsets xml_i="38397" xml_f="38737" txt_i="26203" txt_f="26543">He must notify the sponsor, without delay from the day of his knowledge, of any serious adverse event from the date of signature of the consent, throughout the duration of the patient’s follow-up planned by the research and up to 8 days after the completion of the participant’s research follow-up, where it is likely to be due to research,</offsets></p></sec><sec id="Sec26"><title><offsets xml_i="38770" xml_f="38778" txt_i="26545" txt_f="26553">Auditing</offsets></title><p id="Par87"><offsets xml_i="38800" xml_f="39052" txt_i="26554" txt_f="26806">An audit can be carried out at any time by persons mandated by the promoter and independent of the researchers. Its objective is to ensure the quality of the research, the validity of its results and the respect of the law and the regulations in force.</offsets></p></sec></sec></sec><sec id="Sec27"><title><offsets xml_i="39097" xml_f="39121" txt_i="26810" txt_f="26834">Ethics and dissemination</offsets></title><sec id="Sec28"><title><offsets xml_i="39152" xml_f="39177" txt_i="26835" txt_f="26860">Regulatory authorizations</offsets></title><p id="Par88"><offsets xml_i="39199" xml_f="39844" txt_i="26861" txt_f="27506">All of the authorizations required in accordance with French legislation were obtained for this study: Agence Nationale de Sécurité du Médicament (ANSM) (authorization dated 10/05/2013), Comité Consultatif sur le Traitement de l’Information en matière de Recherche dans le domaine de la Santé (CCTIRS) (Approval Granted on 22/05/2013), Comité de Protection des Personnes (CPP) Sud-Ouest et Outre-Mer (SOOM) (Approval Granted on 27/05/2013), Commission Nationale Informatique et Libertés (CNIL) (Approval Granted on 22/10/2013). This study has been assigned the following numbers: ClinicalTrials No. NCT01955031 and ID-RCB number: 2013-A00391-44.</offsets></p></sec></sec><sec id="Sec29" sec-type="discussion"><title><offsets xml_i="39905" xml_f="39915" txt_i="27509" txt_f="27519">Discussion</offsets></title><p id="Par89"><offsets xml_i="39937" xml_f="40404" txt_i="27520" txt_f="27987">We hope that the telemonitoring of patients in their own home will lead to new organizational management methods in response to relevant follow-up (consultations not scheduled in advance and appointments made depending on the patients’ state of health). Furthermore, refocusing targets based on the information recorded should have a beneficial impact on patient knowledge, behavior and blood glucose management, preventing diabetic complications in the longer term [</offsets><xref ref-type="bibr" rid="CR22"><offsets xml_i="40437" xml_f="40439" txt_i="27987" txt_f="27989">22</offsets></xref><offsets xml_i="40446" xml_f="40893" txt_i="27989" txt_f="28436">]. Apart from medication, the management of patients with type 2 diabetes is multi-faceted and includes education to promote greater independence, the monitoring of blood glucose levels and changes in lifestyle. It is not easy to change the lifestyle of patients who are set in their ways or to find out more about their physical activities and daily diet. Similarly, it is not easy to sustain the change of attitude needed to control the disease.</offsets></p><p id="Par90"><offsets xml_i="40911" xml_f="41189" txt_i="28437" txt_f="28715">Teleeducation tools and connected health devices for telemonitoring purposes can provide both doctors and patients with objective data to discuss optimum solutions on a case-by-case basis. The connected devices per se can be used to teach patients with the support of coaching [</offsets><xref ref-type="bibr" rid="CR23"><offsets xml_i="41222" xml_f="41224" txt_i="28715" txt_f="28717">23</offsets></xref><offsets xml_i="41231" xml_f="41233" txt_i="28717" txt_f="28719">].</offsets></p><p id="Par91"><offsets xml_i="41251" xml_f="41515" txt_i="28720" txt_f="28984">We hope that telemonitoring over several months of patients with type 2 diabetes will provide patients with a better understanding of what they need to do to improve blood glucose management and give them the incentive to continue their efforts in the longer term.</offsets></p><p id="Par92"><offsets xml_i="41533" xml_f="41751" txt_i="28985" txt_f="29203">Apart from the primary objective concerning blood glucose management, the results of the secondary objectives concerning weight, diet and quality of life should enable us to set targets which are more patient-specific.</offsets></p><p id="Par93"><offsets xml_i="41769" xml_f="41895" txt_i="29204" txt_f="29330">The cost-efficacy study will help to establish the economic model to be considered in order to continue this type of activity.</offsets></p><p id="Par94"><offsets xml_i="41913" xml_f="42275" txt_i="29331" txt_f="29693">In conclusion, educating patients at home about a balanced diet and physical exercise could be extended to a bigger diabetic cohort if it proves to be cost-effective. Education concerning diet and the introduction of appropriate physical exercise could be used to educate patients with other chronic cardiovascular diseases, obesity or respiratory diseases, etc.</offsets></p><p id="Par95"><offsets xml_i="42293" xml_f="42585" txt_i="29694" txt_f="29986">The telemonitoring of chronic diseases is in its beginning. Other studies should highlight patient-specific telemonitoring tools (suitable patients, when, for how long, combination or individual telemonitoring and teleeducation, delegation of tasks and the role of treating physicians, etc.).</offsets></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ANSM</term><def><p id="Par4">Agence Nationale de Sécurité du Médicament (French National Agency for the Safety of Medicines)</p></def></def-item><def-item><term>BMI</term><def><p id="Par5">body mass index</p></def></def-item><def-item><term>CCTIRS</term><def><p id="Par6">Comité Consultatif sur le Traitement de l’Information en matière de Recherche dans le domaine de la Santé (French Advisory Committee on Information Processing in Material Research in the Field of Health)</p></def></def-item><def-item><term>CNIL</term><def><p id="Par7">Commission Nationale Informatique et Libertés (French National Commission on Data Processing and Liberty)</p></def></def-item><def-item><term>CPP</term><def><p id="Par8">Comité de Protection des Personnes–EC (Ethics Committee)</p></def></def-item><def-item><term>CRA</term><def><p id="Par9">clinical research assistant</p></def></def-item><def-item><term>CRF</term><def><p id="Par10">clinical report form</p></def></def-item><def-item><term>DQOL</term><def><p id="Par11">diabetes quality of life</p></def></def-item><def-item><term>EQ5D</term><def><p id="Par12">EuroQol five dimensions questionnaire</p></def></def-item><def-item><term>GPAQ</term><def><p id="Par13">global physical activity questionnaire</p></def></def-item><def-item><term>HAS</term><def><p id="Par14">Haute Autorité de Santé (French Health Authorities)</p></def></def-item><def-item><term>HbA1c</term><def><p id="Par15">glycated hemoglobin</p></def></def-item><def-item><term>ICH/GCP</term><def><p id="Par16">International Conference on Harmonisation/Good Clinical Practise</p></def></def-item><def-item><term>ITT</term><def><p id="Par17">intent to treat</p></def></def-item><def-item><term>PP</term><def><p id="Par18">per protocol</p></def></def-item><def-item><term>SAE</term><def><p id="Par19">serious adverse event</p></def></def-item><def-item><term>SOP</term><def><p id="Par20">standard operating procedure</p></def></def-item><def-item><term>WHO</term><def><p id="Par21">World Health Organization</p></def></def-item></def-list></glossary><ack><title>Authors’ contributions</title><p>MCT, SSB, JCB and HH contributed to the creation and design of the study. MCT, SSB, JM, ST and MCC were involved in enrolling and monitoring the patients. BL drafted the global study methodology and statistical methods. LM and NC drafted the methodology for the medical-economical evaluation. All authors helped to write the article and have proof-read and approved the final manuscript. The project team includes the coordinating physician, a project manager, part-time dietician, two clinical research assistants (CRA) and a computer engineer. They ensure that the study is carried out properly from a logistic and technical perspective. All authors read and approved the final manuscript.</p><sec id="FPar1"><title>Acknowledgements</title><p id="Par96">We are grateful to all of the participants who have taken the time to take part in this study.</p><p id="Par97">We wish to extend our grateful thanks to the clinical teams at the University Medical Centers of Grenoble, Lyon, Nantes, Nîmes, and Medical Centers of Cahors, Corbeil-Essonnes, Lannemezan, Tarbes, Clinics Ambroise-Paré (Toulouse), Claude Bernard (Albi), Pasteur (Toulouse) and our 2 colleagues practising in independent medical office.</p></sec><sec id="FPar2"><title>Competing interests</title><p id="Par98">The authors declare that they have no competing interests.</p></sec><sec id="FPar3"><title>Availability of data and materials</title><p id="Par99">Not applicable. This manuscript does not contain any data.</p></sec><sec id="FPar4"><title>Consent to participate</title><p id="Par100">All of the patients taking part in this clinical trial have received verbal information and a written Information leaflet and have been able to ask questions about the study to the investigators and study staff. They have willingly signed an informed consent form before starting the trial.</p></sec><sec id="FPar5"><title>Funding</title><p id="Par101">This study is funded by the French Ministry for Health (tender for research programmes focusing on health system performance (PREPS 2012 No. 12-018-0078) and the Regional Advisory Board-Research Project in Clinical Transfer and Standardization in Bio Health, year 1 (No. 11052617) and year 2 (No. 13050630), facilitating compilation of study methodology, data collection, analysis and interpretation, and the publication of results. We wish to thank SANOFI Laboratories for taking part and providing the blood glucose monitors.</p></sec><sec id="FPar6"><title>Publisher’s Note</title><p id="Par102">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">World Health Organization. Global status report on non-communicable diseases 2014. Geneva; 2014. <ext-link ext-link-type="uri" xlink:href="http://www.wsmi.org/wp-content/uploads/2015/01/Global-Status-Report-NCDs-2014.pdf">http://www.wsmi.org/wp-content/uploads/2015/01/Global-Status-Report-NCDs-2014.pdf</ext-link>. Accessed 5 May 2017.</mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">HAS (Haute Autorité de Santé). Synthèse, Guide Parcours de soins Diabète de type 2 de l’adulte. 2014. <ext-link ext-link-type="uri" xlink:href="http://www.has-sante.fr/portail/upload/docs/application/pdf/2014-04/synthese_guide_pds_diabete_t_2_web.pdf">http://www.has-sante.fr/portail/upload/docs/application/pdf/2014-04/synthese_guide_pds_diabete_t_2_web.pdf</ext-link>. Accessed 5 May 2017.</mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">HAS (Haute Autorité de Santé). Rapport d’orientation—Développement de la prescription de thérapeutiques non médicamenteuses validées. 2011. <ext-link ext-link-type="uri" xlink:href="http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-06/developpement_de_la_prescription_de_therapeutiques_non_medicamenteuses_rapport.pdf">http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-06/developpement_de_la_prescription_de_therapeutiques_non_medicamenteuses_rapport.pdf</ext-link>. Accessed 5 May 2017.</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The Diabetes Control and Complications Trial Research Group</collab></person-group><article-title>The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus</article-title><source>N Engl J Med</source><year>1993</year><volume>329</volume><issue>14</issue><fpage>997</fpage></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>UK Prospective Diabetes Study (UKPDS) Group</collab></person-group><article-title>Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33</article-title><source>Lancet</source><year>1998</year><volume>352</volume><fpage>837</fpage><lpage>853</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(98)07019-6</pub-id><pub-id pub-id-type="pmid">9742976</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marina</surname><given-names>Trento</given-names></name><name><surname>Silvia</surname><given-names>Gamba</given-names></name><name><surname>Luigi</surname><given-names>Gentile</given-names></name><name><surname>Giorgio</surname><given-names>Grassi</given-names></name><name><surname>Valerio</surname><given-names>Miselli</given-names></name><name><surname>Gabriel</surname><given-names>Morone</given-names></name><name><surname>Pietro</surname><given-names>Passera</given-names></name><name><surname>Laura</surname><given-names>Tonutti</given-names></name><name><surname>Marco</surname><given-names>Tomalino</given-names></name><name><surname>Piervincenzo</surname><given-names>Bondonio</given-names></name><name><surname>Franco</surname><given-names>Cavallo</given-names></name><name><surname>Massimo</surname><given-names>Porta</given-names></name></person-group><article-title>Rethink Organization to iMprove Education and Outcomes (ROMEO)—a multicenter randomized trial of lifestyle intervention by group care to manage type 2 diabetes</article-title><source>Diabetes Care</source><year>2010</year><volume>33</volume><fpage>745</fpage><lpage>747</lpage><pub-id pub-id-type="doi">10.2337/dc09-2024</pub-id><pub-id pub-id-type="pmid">20103547</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Izquierdo</surname><given-names>R</given-names></name><name><surname>Lagua</surname><given-names>CT</given-names></name><name><surname>Meyer</surname><given-names>S</given-names></name><name><surname>Ploutz-Snyder</surname><given-names>RJ</given-names></name><name><surname>Palmas</surname><given-names>W</given-names></name><name><surname>Eimicke</surname><given-names>JP</given-names></name><name><surname>Kong</surname><given-names>J</given-names></name><name><surname>Teresi</surname><given-names>JA</given-names></name><name><surname>Shea</surname><given-names>S</given-names></name><name><surname>Weinstock</surname><given-names>RS</given-names></name></person-group><article-title>Telemedicine intervention effects on waist circumference and body mass index in the IDEATel project</article-title><source>Diabetes Technol Ther</source><year>2010</year><volume>12</volume><issue>3</issue><fpage>213</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1089/dia.2009.0102</pub-id><pub-id pub-id-type="pmid">20151772</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wootton</surname><given-names>R</given-names></name></person-group><article-title>Twenty years of telemedicine in chronic disease management—an evidence synthesis</article-title><source>J Telemed Telecare</source><year>2012</year><volume>18</volume><issue>4</issue><fpage>211</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1258/jtt.2012.120219</pub-id><pub-id pub-id-type="pmid">22674020</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcolino</surname><given-names>MS</given-names></name><name><surname>Maia</surname><given-names>JX</given-names></name><name><surname>Alkmim</surname><given-names>MB</given-names></name><etal></etal></person-group><article-title>Telemedicine application in the care of diabetes patients: systematic review and meta-analysis</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><issue>11</issue><fpage>e79246</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0079246</pub-id><pub-id pub-id-type="pmid">24250826</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siriwardena</surname><given-names>LS</given-names></name><name><surname>Wickramasinghe</surname><given-names>WA</given-names></name><name><surname>Perera</surname><given-names>KL</given-names></name><etal></etal></person-group><article-title>A review of telemedicine interventions in diabetes care</article-title><source>J Telemed Telecare</source><year>2012</year><volume>18</volume><issue>3</issue><fpage>164</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1258/jtt.2012.SFT110</pub-id><pub-id pub-id-type="pmid">22362832</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holtz</surname><given-names>Bree</given-names></name><name><surname>Lauckner</surname><given-names>Carolyn</given-names></name></person-group><article-title>Diabetes management via mobile phones: a systematic review</article-title><source>Telemed e-Health</source><year>2012</year><volume>18</volume><issue>3</issue><fpage>175</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1089/tmj.2011.0119</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agboola</surname><given-names>S</given-names></name><name><surname>Jethwani</surname><given-names>K</given-names></name><name><surname>Lopez</surname><given-names>L</given-names></name><name><surname>Searl</surname><given-names>M</given-names></name><name><surname>O’Keefe</surname><given-names>S</given-names></name><name><surname>Kvedar</surname><given-names>J</given-names></name></person-group><article-title>Text to move: a randomized controlled trial of a text-messaging program to improve physical activity behaviors in patients with type 2 diabetes mellitus</article-title><source>J Med Internet Res</source><year>2016</year><volume>18</volume><issue>11</issue><fpage>e307</fpage><pub-id pub-id-type="doi">10.2196/jmir.6439</pub-id><pub-id pub-id-type="pmid">27864165</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buisson</surname><given-names>J-C</given-names></name></person-group><article-title>Nutri-Educ, a nutrition software application for balancing meals, using fuzzy arithmetic and heuristic search algorithms</article-title><source>Artif Intell Med</source><year>2008</year><volume>42</volume><issue>3</issue><fpage>213</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1016/j.artmed.2007.12.001</pub-id><pub-id pub-id-type="pmid">18261889</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buisson</surname><given-names>JC</given-names></name><name><surname>Garel</surname><given-names>A</given-names></name></person-group><article-title>Balancing meals using fuzzy arithmetics and heuristic search algorithms</article-title><source>IEEE Trans Fuzzy Syst</source><year>2003</year><volume>1</volume><fpage>68</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1109/TFUZZ.2002.806323</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turnin</surname><given-names>MC</given-names></name><name><surname>Bourgeois</surname><given-names>O</given-names></name><name><surname>Cathelineau</surname><given-names>G</given-names></name><name><surname>Leguerrier</surname><given-names>AM</given-names></name><name><surname>Halimi</surname><given-names>S</given-names></name><name><surname>Sandre-Banon</surname><given-names>D</given-names></name><name><surname>Coliche</surname><given-names>V</given-names></name><name><surname>Breux</surname><given-names>M</given-names></name><name><surname>Verlet</surname><given-names>E</given-names></name><name><surname>Labrousse</surname><given-names>F</given-names></name><name><surname>Bensoussan</surname><given-names>D</given-names></name><name><surname>Grenier</surname><given-names>JL</given-names></name><name><surname>Poncet</surname><given-names>MF</given-names></name><name><surname>Tordjmann</surname><given-names>F</given-names></name><name><surname>Brun</surname><given-names>JM</given-names></name><name><surname>Blickle</surname><given-names>JF</given-names></name><name><surname>Mattei</surname><given-names>C</given-names></name><name><surname>Bolzonella</surname><given-names>C</given-names></name><name><surname>Buisson</surname><given-names>JC</given-names></name><name><surname>Fabre</surname><given-names>D</given-names></name><name><surname>Tauber</surname><given-names>JP</given-names></name><name><surname>Hanaire-Broutin</surname><given-names>H</given-names></name></person-group><article-title>Multicenter randomized evaluation of a nutritional education software in obese patients</article-title><source>Diabetes Metab</source><year>2001</year><volume>27</volume><issue>2</issue><fpage>139</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">11353880</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>American Diabetes Association</collab></person-group><article-title>Clinical practices recommendations 2012. Standards of medical care in diabetes-2012</article-title><source>Diabetes Care</source><year>2012</year><volume>35</volume><issue>Supplement 1</issue><fpage>S11</fpage><lpage>S63</lpage><pub-id pub-id-type="pmid">22187469</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>American Diabetes Association</collab></person-group><article-title>Standards of medical care in diabetes—2015 glycemic targets</article-title><source>Diabetes Care</source><year>2015</year><volume>38</volume><issue>Supplement 1</issue><fpage>S33</fpage><lpage>S40</lpage><pub-id pub-id-type="doi">10.2337/dc15-S009</pub-id><pub-id pub-id-type="pmid">25537705</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">HAS (Haute Autorité de Santé). Fiche mémo-HAS. Stratégie médicamenteuse du contrôle glycémique du diabète de type 2-Objectifs glycémiques. 2013. <ext-link ext-link-type="uri" xlink:href="https://www.has-sante.fr/portail/upload/docs/application/pdf/2013-02/10irp04_synth_diabete_type_2_objectif_glycemique_messages_cles.pdf">https://www.has-sante.fr/portail/upload/docs/application/pdf/2013-02/10irp04_synth_diabete_type_2_objectif_glycemique_messages_cles.pdf</ext-link>. Accessed 5 May 2017.</mixed-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frison</surname><given-names>L</given-names></name><name><surname>Pocock</surname><given-names>SJ</given-names></name></person-group><article-title>SJ Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design</article-title><source>Stat Med</source><year>1992</year><volume>11</volume><fpage>1685</fpage><lpage>1704</lpage><pub-id pub-id-type="doi">10.1002/sim.4780111304</pub-id><pub-id pub-id-type="pmid">1485053</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>JH</given-names></name><name><surname>Chang</surname><given-names>SA</given-names></name><name><surname>Kwon</surname><given-names>HS</given-names></name><name><surname>Choi</surname><given-names>YH</given-names></name><name><surname>Ko</surname><given-names>SH</given-names></name><name><surname>Moon</surname><given-names>SD</given-names></name><name><surname>Yoo</surname><given-names>SJ</given-names></name><name><surname>Song</surname><given-names>KH</given-names></name><name><surname>Son</surname><given-names>HS</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>WC</given-names></name><name><surname>Cha</surname><given-names>BY</given-names></name><name><surname>Son</surname><given-names>HY</given-names></name><name><surname>Yoon</surname><given-names>KH</given-names></name></person-group><article-title>Long-term effect of the internet- based glucose monitoring system on HbA1c reduction and glucose stability: a 30-month follow-up study for diabetes management with a ubiquitous medical care system</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><fpage>2625</fpage><lpage>2631</lpage><pub-id pub-id-type="doi">10.2337/dc05-2371</pub-id><pub-id pub-id-type="pmid">17130195</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montori</surname><given-names>VM</given-names></name><etal></etal></person-group><article-title>The impact of planned care and a diabetes electronic management system on community-based diabetes care, The Mayo Health System Diabetes Translation Project</article-title><source>Diabetes Care</source><year>2002</year><volume>25</volume><fpage>1952</fpage><lpage>1957</lpage><pub-id pub-id-type="doi">10.2337/diacare.25.11.1952</pub-id><pub-id pub-id-type="pmid">12401738</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farmer</surname><given-names>AJ</given-names></name><name><surname>Prevost</surname><given-names>AT</given-names></name><name><surname></surname><given-names>W</given-names></name><name><surname>Craven</surname><given-names>A</given-names></name><name><surname>Sutton</surname><given-names>S</given-names></name><name><surname>Griffin</surname><given-names>SJ</given-names></name><name><surname>Kinmonth</surname><given-names>AL</given-names></name><collab>The Support and Advice for Medication Trial Group</collab></person-group><article-title>Protocole for SAMS (Support advice for medication study)</article-title><source>BMC Family Pract</source><year>2008</year><volume>9</volume><fpage>20</fpage><pub-id pub-id-type="doi">10.1186/1471-2296-9-20</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Charpentier</surname><given-names>G</given-names></name><name><surname>Benhamou</surname><given-names>PY</given-names></name><name><surname>Dardari</surname><given-names>D</given-names></name><name><surname>Clergeot</surname><given-names>A</given-names></name><name><surname>Franc</surname><given-names>S</given-names></name><name><surname>Schaepelynck-Belicar</surname><given-names>P</given-names></name><name><surname>Catargi</surname><given-names>B</given-names></name><name><surname>Melki</surname><given-names>V</given-names></name><name><surname>Chaillous</surname><given-names>C</given-names></name><name><surname>Farret</surname><given-names>A</given-names></name><name><surname>Bosson</surname><given-names>JL</given-names></name><name><surname>Penfornis</surname><given-names>A</given-names></name><collab>on behalf of the TeleDiab Study Group</collab></person-group><article-title>The diabeo software enabling individualized insulin dose adjustments combined with telemedicine support improves HbA1c in poorly controlled type 1 diabetic Patients</article-title><source>Diabetes Care</source><year>2011</year><volume>34</volume><issue>3</issue><fpage>533</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.2337/dc10-1259</pub-id><pub-id pub-id-type="pmid">21266648</pub-id></element-citation></ref></ref-list></back></article>